JP7531379B2 - βアミノ酸誘導体、これを含むキナーゼ阻害剤および医薬組成物ならびにその使用 - Google Patents

βアミノ酸誘導体、これを含むキナーゼ阻害剤および医薬組成物ならびにその使用 Download PDF

Info

Publication number
JP7531379B2
JP7531379B2 JP2020204848A JP2020204848A JP7531379B2 JP 7531379 B2 JP7531379 B2 JP 7531379B2 JP 2020204848 A JP2020204848 A JP 2020204848A JP 2020204848 A JP2020204848 A JP 2020204848A JP 7531379 B2 JP7531379 B2 JP 7531379B2
Authority
JP
Japan
Prior art keywords
compound
kinase
intraocular pressure
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020204848A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021113185A5 (cg-RX-API-DMAC10.html
JP2021113185A (ja
Inventor
志偉 傅
志鵬 劉
翊▲員▼ 陳
佳穆 杜
秋蓮 洪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industrial Technology Research Institute
Original Assignee
Industrial Technology Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industrial Technology Research Institute filed Critical Industrial Technology Research Institute
Publication of JP2021113185A publication Critical patent/JP2021113185A/ja
Publication of JP2021113185A5 publication Critical patent/JP2021113185A5/ja
Application granted granted Critical
Publication of JP7531379B2 publication Critical patent/JP7531379B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020204848A 2019-12-31 2020-12-10 βアミノ酸誘導体、これを含むキナーゼ阻害剤および医薬組成物ならびにその使用 Active JP7531379B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962955683P 2019-12-31 2019-12-31
US62/955,683 2019-12-31

Publications (3)

Publication Number Publication Date
JP2021113185A JP2021113185A (ja) 2021-08-05
JP2021113185A5 JP2021113185A5 (cg-RX-API-DMAC10.html) 2022-04-18
JP7531379B2 true JP7531379B2 (ja) 2024-08-09

Family

ID=74556625

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020204848A Active JP7531379B2 (ja) 2019-12-31 2020-12-10 βアミノ酸誘導体、これを含むキナーゼ阻害剤および医薬組成物ならびにその使用

Country Status (6)

Country Link
US (1) US11608319B2 (cg-RX-API-DMAC10.html)
EP (1) EP3845276B1 (cg-RX-API-DMAC10.html)
JP (1) JP7531379B2 (cg-RX-API-DMAC10.html)
CN (1) CN113121443B (cg-RX-API-DMAC10.html)
ES (1) ES3015621T3 (cg-RX-API-DMAC10.html)
TW (1) TWI777325B (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230038697A (ko) * 2020-07-14 2023-03-21 우한 엘엘 사이언스 앤드 테크놀로지 디벨롭먼트 컴퍼니, 리미티드 Rock 억제제 및 이의 제조 방법과 용도
WO2025143152A1 (ja) 2023-12-27 2025-07-03 全薬工業株式会社 チアゾリル－ピラゾロ［１，５－ａ］ピリジン化合物、およびそのＭＹＬＫ４阻害剤としての使用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005524631A (ja) 2002-01-25 2005-08-18 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用なインダゾール化合物
JP2009506979A (ja) 2005-09-02 2009-02-19 アステラス製薬株式会社 新規化合物
JP2011507850A (ja) 2007-12-21 2011-03-10 ザ スクリプス リサーチ インスティチュート Ｒｈｏキナーゼインヒビターとしてのアニリドおよびアナログ
JP2012525386A (ja) 2009-05-01 2012-10-22 アエリエ・ファーマシューティカルズ・インコーポレーテッド 疾患の治療のための二重機構阻害剤
JP2016510033A (ja) 2013-02-28 2016-04-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 強力なｒｏｃｋ１およびｒｏｃｋ２阻害剤としてのフェニルピラゾール誘導体
WO2019018855A1 (en) 2017-07-21 2019-01-24 Kadmon Corporation, Llc ALPHA PROPELLER PROTEIN KINASE INHIBITORS ("COILED-COIL") ASSOCIATED WITH RHO
WO2019178324A1 (en) 2018-03-14 2019-09-19 Aerie Pharmaceuticals, Inc. Amino-benzoisothiazole and amino-benzoisothiadiazole amide compounds
JP2019529359A (ja) 2016-08-19 2019-10-17 アエリエ ファーマシューティカルズ インコーポレイテッド ベータ−アミノ−イソキノリニルアミド化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8504218B2 (en) 2007-07-31 2013-08-06 General Electric Company Methods and systems for universal input output for vehicle control
WO2010036316A1 (en) 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
KR101768235B1 (ko) 2009-07-28 2017-08-14 오노 야꾸힝 고교 가부시키가이샤 이환식 화합물 및 이의 의약 용도
KR102074020B1 (ko) 2012-07-13 2020-02-05 산텐 세이야꾸 가부시키가이샤 술폰아미드 화합물의 조합
AU2016264220A1 (en) 2015-05-18 2018-01-04 Translational Drug Development Llc Heterocyclic compounds as kinase inhibitors
WO2018094362A1 (en) * 2016-11-21 2018-05-24 Translational Drug Development, Llc Heterocyclic compounds as kinase inhibitors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005524631A (ja) 2002-01-25 2005-08-18 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用なインダゾール化合物
JP2009506979A (ja) 2005-09-02 2009-02-19 アステラス製薬株式会社 新規化合物
JP2011507850A (ja) 2007-12-21 2011-03-10 ザ スクリプス リサーチ インスティチュート Ｒｈｏキナーゼインヒビターとしてのアニリドおよびアナログ
JP2012525386A (ja) 2009-05-01 2012-10-22 アエリエ・ファーマシューティカルズ・インコーポレーテッド 疾患の治療のための二重機構阻害剤
JP2016510033A (ja) 2013-02-28 2016-04-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 強力なｒｏｃｋ１およびｒｏｃｋ２阻害剤としてのフェニルピラゾール誘導体
JP2019529359A (ja) 2016-08-19 2019-10-17 アエリエ ファーマシューティカルズ インコーポレイテッド ベータ−アミノ−イソキノリニルアミド化合物
WO2019018855A1 (en) 2017-07-21 2019-01-24 Kadmon Corporation, Llc ALPHA PROPELLER PROTEIN KINASE INHIBITORS ("COILED-COIL") ASSOCIATED WITH RHO
WO2019178324A1 (en) 2018-03-14 2019-09-19 Aerie Pharmaceuticals, Inc. Amino-benzoisothiazole and amino-benzoisothiadiazole amide compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGISTRY（STN）［online］，2013年，CAS 登録番号：1506916-17-1

Also Published As

Publication number Publication date
TW202126628A (zh) 2021-07-16
EP3845276B1 (en) 2025-01-29
CN113121443A (zh) 2021-07-16
TWI777325B (zh) 2022-09-11
US11608319B2 (en) 2023-03-21
CN113121443B (zh) 2024-07-09
EP3845276A1 (en) 2021-07-07
US20220363645A1 (en) 2022-11-17
JP2021113185A (ja) 2021-08-05
ES3015621T3 (en) 2025-05-06

Similar Documents

Publication Publication Date Title
ES2289349T3 (es) Derivados de heteroaril-pirimidina como inhibidores de jak.
KR102726637B1 (ko) 6-아미노이소퀴놀린의 일가-(산) 염 및 이의 용도
JP7857285B2 (ja) αプロテインキナーゼ１阻害剤及び使用の方法
AU2014204831B2 (en) Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases
JPH05506854A (ja) 局部活性眼用チアジアゾールスルホンアミドカルボニックアンヒドラーゼ抑制剤
CN103025740B (zh) 蛋白酪氨酸激酶活性的抑制剂及其治疗眼科疾病的用途
PT1888548E (pt) Derivado de quinolina para o tratamento de doenças da retina
ES2691805T3 (es) Medicamento para el tratamiento de una enfermedad ocular
JP6291066B2 (ja) ナフチル尿素誘導体およびその医療適用
CN112566670A (zh) 一氧化氮释放第5型磷酸二酯酶抑制剂
US20170065602A1 (en) Compounds with trpv4 activity, compositions and associated methods thereof
CN113121443B (zh) β-氨基酸衍生物、含其之激酶抑制剂与医药组合物以及其用途
ES3002189T3 (en) Para-hydroquinone derivatives as vegf, tnf and/or il inhibitors for the treatment of neuroinflammatory diseases
KR102758256B1 (ko) β-아미노산 유도체, 키나아제 억제제 및 이를 함유하는 약학 조성물
CN111518028B (zh) 一种一氧化氮供体型ripasudil衍生物及其制备方法和用途
JP7834370B2 (ja) 緑内障の治療のためのカルパイン－２選択的阻害剤化合物
JP2019522673A (ja) Ｈｔｒａ１阻害剤としての新規なジフルオロケトアミド誘導体
CN101899008B (zh) N-取代嘧啶磺酰基-取代苯甲酰胺类化合物及其制备药物的用途
CN102666563A (zh) 作为a2a受体激动剂的烷氧基羰基氨基炔基腺苷化合物及其衍生物
CN100422161C (zh) 羟基吗啉酮衍生物及其医药用途
JPWO2019022152A1 (ja) ＴＧＦ−βシグナルに起因する障害を治療または予防するための医薬およびその応用
CN103172619B (zh) 4-(取代苄基)-1(2h)-2,3-二氮杂萘酮类衍生物及其制备方法、药物组合物和用途
TW201329084A (zh) 蛋白酪氨酸激酶活性選擇的抑制劑
HK40049475A (en) Nitric oxide releasing phosphodiesterase type 5 inhibitor
CN103172619A (zh) 4-(取代苄基)-1(2h)-2,3-二氮杂萘酮类衍生物及其制备方法、药物组合物和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220407

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231109

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240508

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240730

R150 Certificate of patent or registration of utility model

Ref document number: 7531379

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150